Manufactures vaccines for diseases like hepatitis, influenza, rubella and typhoid fever

Chiesi Farmaceutici SpA develops and markets pharmaceutical products. The firm specializes in research, development and production of drugs in respiratory dosage forms, such as metered-dose inhalers and sterile unit dose vials. The company was founded by Giacomo Chiesi in 1935 and is headquartered in Parma, Italy.

AstraZeneca has always believed in science, inspires infinite possibilities, and puts science at the top of all work. AstraZeneca's strategically important core treatment areas, and are committed to exploring pathogenic mechanisms, treatment methods, and innovative drugs, so that science can change people's lives and bring it to the medical industry Significant changes.

Smithkline Beckman Corp, part of GSK Plc, is an American company located in Philadelphia, PA, involved in pharmaceutical preparations. On July 27, 1989 Smithkline Beecham Plc acquired Smithkline Beckman Corp for $16,082.37 million.

Geron is a biotechnology company that specializes in developing blood cancer treatments for hematologic malignancies. The company's Imetelstat, an investigational first-in-class telomerase inhibitor, harnesses Nobel Prize-winning science in a treatment that may change the underlying course of these diseases. Geron was established in 1990 and is headquartered in Foster City, California.

Part of Mereo BioPharma Group Plc, Mereo BioPharma 1 Ltd. is a British company located in London that engages in research and development on biotechnology.

MedImmune develops medicines for unmet medical needs worldwide. As the global biologics research and development arm of AstraZeneca, MedImmune is pioneering innovative research and exploring novel pathways across key therapeutic including respiratory, inflammation, and autoimmunity; cardiovascular and metabolic disease; oncology; neuroscience; and infection and vaccines. Since its founding in 1988, MedImmune has remained committed to scientific innovation and medical progress, continually looking beyond standard expectations and pushing the boundaries of what is possible.

ResMed provides sleep medications and non-invasive ventilation based on a visionary technology shifting diagnosis, treatment, and management of breathing sleep disorder. They treat sleep apnea, chronic obstructive pulmonary disease, and other chronic diseases.

Pulmatrix is a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology. The Company's proprietary product pipeline is initially focused on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with ABPA, and PUR1800, a narrow spectrum kinase inhibitor in lung cancer. Pulmatrix's product candidates are based on iSPERSE™, its proprietary engineered dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by achieving optimal local drug concentrations and reducing systemic side effects to improve patient outcomes.

RespiVert Ltd. operates as a small molecule drug discovery company. The firm develops small-molecule inhaled therapies for the treatment of chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis. The company was founded by William Garth Rapeport, Peter Strong, Kazuhiro Ito, John Murray and Peter Barnes in 2007 and is headquartered in London, the United Kingdom.

Part of Asahi Kasei Corp., Asahi Kasei Pharma Corp. is a Japanese company located in Tokyo that functions as an alternative investment manager. The firm was founded in 2003.\nThe company says this about itself: Asahi Kasei Pharma Corporation, headquartered in Tokyo, Japan, is a research-based health care innovator that discovers, develops, manufactures, and markets pharmaceuticals and diagnostic products. Asahi Kasei Pharma is a wholly owned business unit of Asahi Kasei Corporation, a US $20 billion technology company, that provides innovative, science-based solutions to a diverse range of markets including healthcare, chemicals and fibers, housing and construction materials, and electronics.

MediciNova is a biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Through strategic alliances primarily with Japanese pharmaceutical companies, MediciNova holds rights to a diversified portfolio of clinical and preclinical product candidates, each of which MediciNova believes has a well-characterized and differentiated therapeutic profile, attractive commercial potential and patent assets having claims of commercially adequate scope. MediciNova’s pipeline includes clinical-stage compounds for the treatment of acute exacerbations of asthma and COPD, progressive multiple sclerosis, methamphetamine addiction, neuropathic pain, asthma, interstitial cystitis, and solid tumor cancers

Aseptika Ltd. develops and markets an integrated suite of self-monitoring devices and services. Its products include buddy step counter, body analyzer bluetooth smart scales, blood pressure monitor, pulse oximeter, smart one peak flow and contactless infrared thermometer bluetooth. Its healthcare solutions include self-monitoring, biomarker tests, always connected, clinical trials, corporate wellness and healthcare collaborators. The company was founded by Kevin A. Auton and Jessica Auton in 2007 is headquartered in Huntingdon, the United Kingdom.

Yinchuan Shanghetu New Technology R&D Co., Ltd., established on 2013-10-28, Business scope includes research and development of practical new technologies;Research and development of high-tech popularization methods;Research and development of new educational methods;Health products,Food and its quality preservation technology,Research and Development of Fresh Fruit and Vegetable Preservation Technology;Food and dried and fresh fruit packaging sales;Production and sales of plastic packaging containers.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Biota Scientific Management Pty Ltd., a subsidiary of Vaxart, Inc., is an Australian company located in Notting Hill that develops anti-infective drugs.

two quirky scientists vowed to make the world a better place. After learning their trades in some of the world’s biggest scientific organisations, Paul and Mark Davis (father and son team with a striking resemblance to Pinky and the Brain established Mologic to do as much good as possible in healthcare and education. They want to improve patient care and quality of life, and break new ground in exciting fields of research (unlike Pinky and the Brain who wanted to take over the world).

Kamada is a biopharmaceutical company engaged in developing, producing and marketing of specialty life-saving therapeutics, using a unique protein purification technology. Kamada's product line consists of more than 10 injectable pharmaceutical products which are marketed in more than 15 countries worldwide. The Company's pharmaceuticals are produced in its state-of-the-art, cGMP-compliant, FDA-approved, large scale production facility. Kamada’s flagship product is Glassia®; an FDA approved intravenous (IV) Alpha-1 Antitrypsin (AAT) protein, for the treatment of AAT Deficiency. Glassia® is a high purity, ready to use and stabilizer free augmentation treatment. Kamada has a strategic agreement with Baxter for US marketing, distribution and licensing of Glassia®. Kamada’s second generation AAT product is an inhaled (IH) version. This product is already in advanced stages of clinical development for the treatment of AAT Deficiency. Other potential indications for AAT (IV or IH) include bronchiectasis, cystic fibrosis, COPD as well as type-1 diabetes for which the Company started a clinical trial. In addition to its capabilities to manufacture specialty proteins, Kamada has developed a platform technology for the production of specific immunoglobulins (IgGs). Kamada's unique know-how and capabilities enable it to seek new business opportunities and offer a wide scope of pharma-oriented services, including: R&D of new biopharmaceuticals, large scale production of high quality biopharmaceuticals, formulation and aseptic filling, registration and marketing. Over the years Kamada has established its presence in the pharma industry worldwide. Kamada’s mission is to develop, manufacture and provide high quality, specialty pharmaceuticals to patients, in order to support better quality of life and save lives.

Vaccinex has developed an antibody discovery platform that enables efficient mammalian cell-based expression for expression of large and diverse libraries of high affinity, full-length human monoclonal antibodies on the surface envelope of a mammalian virus and the cell surface membrane of the infected cell. This allows them to combine the advantages of virus panning and cell sorting into one seamless selection process. This technology enables the rapid selection of 1010 antibody combinations and thus selection of high affinity leads with varied frameworks that recognize multiple epitopes. It is based in Rochester, New York.